Navigation Links
Following a Record Year in 2008 Gerresheimer Again Sets its Sights on Substantial Growth in 2009
Date:2/17/2009

    DUSSELDORF, Germany, February 17 /PRNewswire/ --

    - Sales Grow by 10.7% to EUR1.06bn

    - Adjusted Earnings per Share Improves by 36.6% From EUR1.34 Euro to
      EUR1.83

    - Adjusted EBITDA Margin Rises From 19.0 to 19.5%

    - CEO Dr. Axel Herberg: "Following the record year in 2008 Gerresheimer
      again considers itself well equipped to meet the global challenges in
      2009 and is aiming for further substantial sales growth of 6% to 7% in
      the core business."

In 2008 Gerresheimer AG had another record year marked by important milestones, and achieved all its published objectives. The international Group with its main base in Dusseldorf, Germany, increased its sales by 10.7% (12.8% on a like-for-like exchange-rate basis) and thereby passed the billion euro mark. Operating results (Adjusted EBITDA) rose by 13.7% to EUR206.4m (prior year: EUR181.6m). The Adjusted EBITDA margin reached 19.5% in 2008 (prior year: 19%). There was a substantial improvement of 36.6% in adjusted earnings per share in the past financial year to EUR1.83 (prior year EUR1.34).

"Our strategy of internationalization and focus is bearing fruit," says Dr. Axel Herberg, CEO of Gerres-heimer AG. "Even in a phase of worldwide economic downturn, pharmaceutics and life science are still growth markets and, with its broad technology base and worldwide presence, Gerresheimer has a strong position here." The shareholders of Gerresheimer AG should participate in the success of Gerresheimer AG as in the prior year. The Management Board and Supervisory Board of Gerresheimer AG will therefore propose to the Shareholders' Meeting that a dividend of EUR0.40 per share is paid.

In December 2008, Gerresheimer AG was included in the second-largest German selection index MDax. This means increased visibility for our company on capital markets, and greater appeal for our shares.

Further substa
'/>"/>

SOURCE Gerresheimer AG
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiogaphic Data Safety Monitoring Board Review
2. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiographic Data Safety Monitoring Board Review
3. Rosetta Genomics Announces Initiation of In Vivo Studies Following Successful Completion of First Milestone in MicroRNA-based Therapeutic Program for Liver Cancer
4. Sigma-Aldrich Achieves Double Accreditation as a Certified Reference Material Producer Following ISO/IEC 17025 and ISO Guide 34
5. In response to a New England Journal of Medicine article published yesterday and subsequent media coverage, Eli Lilly and Company issued the following statement:
6. Velcura Therapeutics, Inc. Can Begin Clinical Trials Following Successful Investigational New Drug Application to U.S. FDA
7. Cardiums Corgentin Preclinical Program Shows High Levels of Targeting to Acutely Ischemic Heart Muscle Following Intracoronary Infusion
8. Nereus Pharmaceuticals Initiates Clinical Trial of NPI-2358 in Non-Small Cell Lung Cancer Following Encouraging Phase 1 Data
9. ITSSD: Russia Can Secure Greatest Biotech Market Advances Following US, Not EU Innovation Model
10. Following a Good Start to the Year Shire Reaffirms Full Year 2008 Financial Guidance
11. Baxter Raises Full-Year 2008 Outlook Following Strong Second-Quarter Financial Results

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...ire-FirstCall/--GenomicHealth,Inc.(Nasdaq: GHDX )t...veChairman,willpresentatthe21stAnnualPiperJaffrayH...1,2009at10:00a.m.ET. ,, Toaccesstheliveandsubse...vestorRelationssectionofGenomicHealth,swebsiteat h...hewebsiteatleast15minutespriortothebeginningofthep...
(Date:11/24/2009)...cts Service (CAS), the global expert on chemical i...now the world,s leading producer of patent inventi...s patent office, the World Intellectual Property O...nd Trademark Office (USPTO) for more than a decade...exceeded Japan for the first time on a monthly bas...
(Date:11/23/2009)... origami very high-tech origami. , Researchers a...nique for fabricating three-dimensional, single-cr...upling photolithography and a self-folding process...nly a few microns thick, offer mechanical bendabil...e same material. , "This is a completely differen...
(Date:11/23/2009)...wire-FirstCall/--PDLBioPharma,Inc.(PDL)(Nasdaq: PD...27,2009astheex-dividenddateforits$200millionspecia...iontransactioncompletedonNovember2,2009.Thedividen...ordontherecorddate,December1,2009.NASDAQhassetthea...reofcommonstockforpurposesoftheex-dividenddateonNo...
Breaking Biology Technology:Genomic Health to Present at Piper Jaffray Health Care Conference 2China Leads All Nations in Publication of Chemical Patents According to CAS, the World's Most Authoritative Publisher of Chemical Information 2China Leads All Nations in Publication of Chemical Patents According to CAS, the World's Most Authoritative Publisher of Chemical Information 3Water droplets direct self-assembly process in thin-film materials 2PDL BioPharma Announces Ex-Dividend Date of November 27 for Special Dividend 2
...e Market Share Away from Lucentis from 2012 to 201...es , , WALTHAM, Mass., March 10 Decision Resourc...ry firms for pharmaceutical and healthcare issues,... age-related macular degeneration (AMD) market thr...e of Genentech/Novartis Ophthalmics, Lucentis in E...
..., Inc. (Nasdaq: NXTM ), a leading manufacturer o...at Jeffrey H. Burbank, Chief Executive Officer, wi...ual Healthcare Conference on Monday, March 16, 200... NxStage,s investor presentation is scheduled for ...the audio webcast of the presentation, please visi...
...er Key Regulatory Milestone , , LONDON, March 10 ...development in breeding and biotechnology has cont...e for the company,s Seeds and Genomics segment sin...eete, Monsanto,s Vice President of International C...presentation at the Credit Suisse 14th Annual Glob...
Other Biology Technology:Robust Annual Growth Through 2012 in the Age-Related Macular Degeneration Market Will Be Driven by Expanding Use of Lucentis in Europe 2Robust Annual Growth Through 2012 in the Age-Related Macular Degeneration Market Will Be Driven by Expanding Use of Lucentis in Europe 3NxStage to Present at the Cowen and Company 29th Annual Healthcare Conference 2Monsanto's Historic R&D Investment has Contributed to Mid-20s Gross Profit Growth for Its Seeds and Genomics Segment 2Monsanto's Historic R&D Investment has Contributed to Mid-20s Gross Profit Growth for Its Seeds and Genomics Segment 3
(Date:11/23/2009)...he Interuniversity Professorship in Law and the Hu...y of the Basque Country. The Professorship is larg...such as researchers in the fields of molecular bio... The Interuniversity Professorship in Law and the ...e Basque Country was created in 1993. The worldwid...
(Date:11/23/2009)...g dangers to human health and the environment. Nor...oject with funding from the U.S. Environmental Pro...se that contribute to millions of overflows every ...rther reduce the risk of sewage spills. , At iss... opposed to "combined" systems that also handle st...
(Date:11/23/2009)..., Of all global carbon dioxide emissions, less ...ntributes to global warming. The remainder is hidd...as forests, grasslands and peat-lands. Stimulating...osystems is considered one of the main, immediatel...er, new greenhouse gas bookkeeping has revealed th...
Breaking Biology News(10 mins):Research and legislation should go hand in hand, as much as possible 2Lose the fat: Targeting grease to curtail sewer overflows 2Intensive land management leaves Europe without carbon sinks 2Innovation and Global Clinical Trial Participation are the Focus of CenterWatch 26apos 3Bs Latest Special Report on China 26apos 3Bs Drug Development 58456 1Innovation and Global Clinical Trial Participation are the Focus of CenterWatch 26apos 3Bs Latest Special Report on China 26apos 3Bs Drug Development 58456 2New perspectives on cancer surgery 58454 1New perspectives on cancer surgery 58454 2Transgenic songbirds provide new tool to understand the brain 10150 1Transgenic songbirds provide new tool to understand the brain 10150 2
...een the body clock and abnormalities in metabolism...y an international team involving the University o...the MRC Epidemiology Unit in Cambridge. , The res...y the body responds to the 24 hour day-night cycle...s and an increased risk of type 2 diabetes. The re...
...ges a real aim of genetics: to look at whole popul...ndividual genetic variants for individual health. ...ure Genetics , find six novel genetic variants tha...ator of heart or artery disease. , The power of ,...hods are in place to study many thousands of DNA s...
... Rather than infer that nanotechnology is safe, m...ience tend to become sharply polarized along cultu...ultural Cognition Project at Yale Law School in co...ologies. The report is published online in the jou...ve important implications for garnering support of...
Other Biology News:Discovery of new gene associated with diabetes risk suggests link with body clock 2The genetic heart of the lipids 2The genetic heart of the lipids 3Nanotechnology 'culture war' possible, says Yale study 2
...it I provides reagents and a protein standard for ...of reducing agents and detergents. The RC DC prote... reagents and standards sufficient for 500 standar...I, 250 ml alkaline copper tartrate solution, 2 L d...
Gelatin from bovine skin from Sigma-Aldrich
...-the-art separation system using the asymmetric fl...Eclipse integrates easily with Wyatts multi-angle ...N Tristar, as well as the Optilab DSP. The combine...tributions of the particles/molecules separated by...
... for determining the absolute count of CD34+ cells...pheral blood samples, and leukapheresis samples. T...leated cell count and a total CD45 (leucocyte) cel...ocount progenitor cell enumeration system. Specie...
Biology Products: